Post-Marketing Safety Profile of Cladribine in Multiple Sclerosis: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System

    November 2025 in “ International Journal of Clinical Pharmacy ”
    Yu‐Wen Hu, Jun He, Zhengkai Tu … Qiong Yao
    Studysummary This study confirms known risks of cladribine and reveals potential new safety concerns, emphasizing the need for careful monitoring for early acute toxicity.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on link.springer.com →
    Discuss this study in the Community →

    Research cited in this study 1

    1. The Quality of Life and Psychosocial Impact on Female Pattern Hair Loss Annals of Dermatology · 2024